Terms: = Leukemia AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Diagnosis
38 results:
1. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract] [Full Text] [Related]
2. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
[TBL] [Abstract] [Full Text] [Related]
3. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia.
Sarno J; Domizi P; Liu Y; Merchant M; Pedersen CB; Jedoui D; Jager A; Nolan GP; Gaipa G; Bendall SC; Bava FA; Davis KL
Nat Commun; 2023 May; 14(1):2935. PubMed ID: 37217509
[TBL] [Abstract] [Full Text] [Related]
4. Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response.
Martinez-Sanchez J; Palomo M; Pedraza A; Moreno-Castaño AB; Torramade-Moix S; Rovira M; Salas MQ; Cid J; Escolar G; Penack O; Carreras E; Diaz-Ricart M
J Cell Mol Med; 2023 May; 27(9):1227-1238. PubMed ID: 37016544
[TBL] [Abstract] [Full Text] [Related]
5. The roles and mechanisms of circular RNAs related to mtor in cancers.
Cao C; Wang Y; Wu X; Li Z; Guo J; Sun W
J Clin Lab Anal; 2022 Dec; 36(12):e24783. PubMed ID: 36426933
[TBL] [Abstract] [Full Text] [Related]
6. [Pure red cell aplasia: diagnosis, classification and treatment].
Lobbes H
Rev Med Interne; 2023 Jan; 44(1):19-26. PubMed ID: 36336519
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Zhai Y; Singh P; Dolnik A; Brazda P; Atlasy N; Del Gaudio N; Döhner K; Döhner H; Minucci S; Martens J; Altucci L; Megchelenbrink W; Bullinger L; Stunnenberg HG
Mol Cancer; 2022 Aug; 21(1):166. PubMed ID: 35986270
[TBL] [Abstract] [Full Text] [Related]
8. LINC00092 Modulates Oxidative Stress and Glycolysis of Breast Cancer Cells via Pyruvate Carboxylase-Mediated AKT/mtor Pathway.
Chen W; Liu Y; Kang S; Lv X; Fu W; Zhang J; Song C
Oxid Med Cell Longev; 2022; 2022():5215748. PubMed ID: 35799892
[TBL] [Abstract] [Full Text] [Related]
9. In silico comprehensive analysis of coding and non-coding SNPs in human mtor protein.
Yasmin T
PLoS One; 2022; 17(7):e0270919. PubMed ID: 35788771
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of serum lipid parameters predicting lipid metabolic disorders in TSC-AML patients with treatment of mtor inhibitors.
Wang W; Wang Z; Zhao Y; Wang X; Li H; Zhang Y
J Clin Pharm Ther; 2022 Jul; 47(7):979-985. PubMed ID: 35229896
[TBL] [Abstract] [Full Text] [Related]
11. Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mtor pathways dominates the single-cell phosphosignature of
Kuzilková D; Bugarin C; Rejlova K; Schulz AR; Mei HE; Paganin M; Biffi A; Biondi A; Kalina T; Gaipa G
Haematologica; 2022 Jun; 107(6):1293-1310. PubMed ID: 34670357
[TBL] [Abstract] [Full Text] [Related]
12. TRIB3 promotes proliferation, migration, and invasion of retinoblastoma cells by activating the AKT/mtor signaling pathway.
Bao XY; Sun M; Peng TT; Han DM
Cancer Biomark; 2021; 31(4):307-315. PubMed ID: 33896816
[TBL] [Abstract] [Full Text] [Related]
13. Clinical characteristics and gene mutation analysis of clear cell tumor of the lung.
Wu S; Pan D; Chen W; Ren F; Zheng D; Liu K
Indian J Pathol Microbiol; 2021; 64(2):362-368. PubMed ID: 33851636
[TBL] [Abstract] [Full Text] [Related]
14. miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.
Lucafò M; Sicari D; Chicco A; Curci D; Bellazzo A; Di Silvestre A; Pegolo C; Autry R; Cecchin E; De Iudicibus S; Collavin L; Evans W; Decorti G; Stocco G
Cancer Chemother Pharmacol; 2020 Sep; 86(3):361-374. PubMed ID: 32776229
[TBL] [Abstract] [Full Text] [Related]
15. Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach.
Nason GJ; Morris J; Bhatt JR; Richard PO; Martin L; Ajib K; Tan GH; Jewett MAS; Jhaveri K; Zlotta AR; Lee JY; Perlis N; Hamilton RJ; Finelli A
Eur Urol Focus; 2021 May; 7(3):582-588. PubMed ID: 32636160
[TBL] [Abstract] [Full Text] [Related]
16. Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mtor Signaling.
Tohumeken S; Baur R; Böttcher M; Stoll A; Loschinski R; Panagiotidis K; Braun M; Saul D; Völkl S; Baur AS; Bruns H; Mackensen A; Jitschin R; Mougiakakos D
Cancer Res; 2020 Sep; 80(17):3663-3676. PubMed ID: 32605996
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCR‑ABL/AKT/mtor pathway.
Zhang Z; Li N; Liu S; Jiang M; Wan J; Zhang Y; Wan L; Xie C; Le A
Int J Mol Med; 2020 Apr; 45(4):1187-1194. PubMed ID: 32124954
[TBL] [Abstract] [Full Text] [Related]
18. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.
James AR; Schroeder MP; Neumann M; Bastian L; Eckert C; Gökbuget N; Tanchez JO; Schlee C; Isaakidis K; Schwartz S; Burmeister T; von Stackelberg A; Rieger MA; Göllner S; Horstman M; Schrappe M; Kirschner-Schwabe R; Brüggemann M; Müller-Tidow C; Serve H; Akalin A; Baldus CD
J Hematol Oncol; 2019 Jan; 12(1):8. PubMed ID: 30642353
[TBL] [Abstract] [Full Text] [Related]
19. Microenvironment-induced PIM kinases promote CXCR4-triggered mtor pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract] [Full Text] [Related]
20. Dual inhibition of PI3K/mtor signaling in chemoresistant AML primary cells.
Bertacchini J; Frasson C; Chiarini F; D'Avella D; Accordi B; Anselmi L; Barozzi P; Forghieri F; Luppi M; Martelli AM; Basso G; Najmaldin S; Khosravi A; Rahim F; Marmiroli S
Adv Biol Regul; 2018 May; 68():2-9. PubMed ID: 29576448
[TBL] [Abstract] [Full Text] [Related]
[Next]
